Khuder SA, Foos M, Herial NA, Mutgi AB, Khuder BS, Jung R.  Urban/rural differences in hospital admissions with multiple sclerosis in selected counties in Ohio 1999-2004.  Open Epidemiol J 2009;2:51-4.

Cappelletty DM, Jung R.  Anidulafungin and its role in candida infections.  Infect Drug Resist 2009; 2:51

Juang P, Fish DN, Jung R, MacLaren R. Enteral glutamine supplementation in critically ill patients with burn injuries: a retrospective case-control evaluation. Pharmacotherapy. 2007 Jan;27(1):11-9.

Seo YS, Lee SH, Shin EK, Kim SJ, Jung R, HahnTW.  Pulsed-field gel electrophoresis genotyping of  Salmonella gallinarum and comparison with random amplified polymorphic DNA genotyping. Vet Microbiol 2006;115:349-57.

MacLaren R, Obritsch O, Sherman D, Jung R, Fish D.  Assessing Adherence to an Intravenous Pantoprazole Guideline. Journal of Pharmacy Technology  2006:2215-21.

Kiser T, Jung R, MacLaren R, Fish D.  Evaluation of Direct Thrombin Use in Patients with Proven or Suspected Heparin Induced Thrombocytopenia (HIT).  Pharmacotherapy  2005;12: 1736-45.

Obritsch MD, Fish DN, MacLaren R, Jung R.  Nosocomial Infections due to Multidrug Resistant Pseudomonas aeruginosa: A Focus on Epidemiology and Treatment Options.  Pharmacotherapy  2005;25:1353-64.

Kiser T, Fish DN, Obritsch, Jung R, MacLaren R, Parikh CR.  Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.  Nephrology, Dialysis and Transplantation  2005:20:1813-20.

Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF.  Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist to reconstituted lyophilized formulation.  J Pharm Sci. 2005 94:382-96.

Jung R, Hussain M, Choi MK, Fish DF.  Synergistic activities of moxifloxacin alone and in combination with piperacillin/tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.  Antimicrob Agents Chemother 2004;48:1055-1057.

Jung R, Fish DN, Obritsch MD, MacLaren R.  Surveillance of Multi-Drug Resistant Pseudomonas aeruginosa in the Urban Tertiary-Care Teaching Hospital.  J Hosp Infect 2004;57:105-111.

Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, Danziger LH.  The beneficial impact of long-term clarithromycin therapy in subjects with corticosteroid-dependent asthma.  Curr Therap Res 2004;65:1-12.

MacLaren R, Gasper J, Jung R,  Vandivier RW,.  Rationalizing the Use of Exogenous Erythropoietin in Critically Ill Patients.  Clin Pharm Therap 2004;29:195-208.

Obritsch MD, MacLaren R, Jung R, Fish DN.  Effects of Continuous Vasopressin Infusion in Patients with Septic Shock. Ann Pharmacother 2004;38:1117-1122.

Obritsch MD, Bestul D, Jung R, Fish DN, MacLaren R.  Role of Vasopressin in Vasodilatory Septic Shock.  Pharmacother 2004;24:1050-1063.

Obritsch MD, Fish DN, MacLaren R Jung R.  Incidence of Multi-Drug Resistant Pseudomonas  aeruginosa in the United States, 1993-2002.  Antimicrob Agents Chemother 2004;48:4606-4610.

Jung R, Pendland SL, Martin SJ.  The effect of partial liquid ventilation with perfluorooctylbromide on bacterial growth. Chemother 2003;49(1-2):1-7.

Dugan HA, MacLaren R, Jung R.  Short-course antibiotic therapy for nosocomial pneumonia. J Clin Pharm Therap 2003; 28:1-6

Tesoro EP, Jung R, Messick CR, Martin SJ, Pendland SL.  In vitro evaluation of antibiotic combinations against hospital-acquired isolates of Stenotrophomonas maltophilia.  J Appl Res 2003; 3 (2):1-5

Fish DN, Choi MK, Jung R.  Synergistic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs.  J Antimicrob Chemother 2002;50:1045-1049.

Jung R, Pendland SL, Martin SJ.  Combined bactericidal activity of perfluorooctyl bromide and aminoglycosides against Pseudomonas aeruginosa.  J Antimicrob Chemother 2002;50:939-944.

Jung R, MacLaren R.  Proton pump inhibitors for the prevention of stress related mucosal bleeding in critically ill patients.  Ann Pharmacother 2002;36:1929-1937.

Neuhauser MM, Jung R, Danziger LH, Pendland SL.  In vitro bactericidal activity of ABT-773 versus four other agents against Streptococcus pneumoniae and Haemophilus influenzae.  Int J Antimicrob Agents 2002; 20:395-398.

Pendland SL, Neuhauser MM, Garey KW, Prause JL, Jung R.  Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration.  Diagn Microb Infect Dis 2002; 44:59-61.

MacLaren R, Jung R.  Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults.  Pharmacother 2002; 22(9):1140-1156.

Pendland SL, Jung R, Messick CR, Schriever CA, Patka J.  In vitro bactericidal activity of piperacillin, gentamicin, and metronidazole in a mixed model containing Escherichia coli, Enterococcus faecalis, and Bacteroides fragilis. Diagn Micro Infect Dis.  2002; 43(2):149-156.

Jung R, LI DH, Pendland SL, Danziger LH.  Intracellular activity of ABT-773 and other antimicrobial agents  against Legionella pneumophila isolates.  J Antimicrob Chemother 2002; 49: 857-861.

Pendland SL, Messick CR, Jung R. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa.  Diagn Microbiol Infect Dis 2002; 42:75-78.

Martin SJ, Jung R, Garvin CG.  A Risk-Benefit Assessment of Levofloxacin In Respiratory, Skin and Skin Structure, and Urinary Tract Infections.  Drug Safety 2001;24(3):199-222.

Jung R, Messick CR, Pendland SL.  Postantibiotic effect and bactericidal activity of clarithromycin/14-hydroxy clarithromycin against Bacteroides fragilis.  Antimicrob Agent Chemother.  2000;44(3):778-779.